Molecular monitoring to improve outcomes in patients with chronic myeloid leukemia in chronic phase: importance of achieving treatment-free remission.
Publication
, Journal Article
Erba, HP
Published in: Am J Hematol
March 2015
Imatinib was the first BCR-ABL1 tyrosine kinase inhibitor (TKI) developed for the treatment of patients with chronic myeloid leukemia (CML); subsequently, the introduction of more potent BCR-ABL1 TKIs has raised expectations regarding the speed and depth of response. This review discusses how molecular monitoring is being used as an integral part of the treatment regimen to achieve improved outcomes in patients with CML. The long-term prognostic implications of achieving early molecular response to TKI therapy and the feasibility of maintaining treatment-free remission will also be discussed in light of current clinical data.
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Am J Hematol
DOI
EISSN
1096-8652
Publication Date
March 2015
Volume
90
Issue
3
Start / End Page
242 / 249
Location
United States
Related Subject Headings
- Remission Induction
- Randomized Controlled Trials as Topic
- Pyrimidines
- Protein Kinase Inhibitors
- Prognosis
- Piperazines
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Immunology
- Imatinib Mesylate
- Humans
Citation
APA
Chicago
ICMJE
MLA
NLM
Erba, H. P. (2015). Molecular monitoring to improve outcomes in patients with chronic myeloid leukemia in chronic phase: importance of achieving treatment-free remission. Am J Hematol, 90(3), 242–249. https://doi.org/10.1002/ajh.23902
Erba, Harry P. “Molecular monitoring to improve outcomes in patients with chronic myeloid leukemia in chronic phase: importance of achieving treatment-free remission.” Am J Hematol 90, no. 3 (March 2015): 242–49. https://doi.org/10.1002/ajh.23902.
Erba HP. Molecular monitoring to improve outcomes in patients with chronic myeloid leukemia in chronic phase: importance of achieving treatment-free remission. Am J Hematol. 2015 Mar;90(3):242–9.
Erba, Harry P. “Molecular monitoring to improve outcomes in patients with chronic myeloid leukemia in chronic phase: importance of achieving treatment-free remission.” Am J Hematol, vol. 90, no. 3, Mar. 2015, pp. 242–49. Pubmed, doi:10.1002/ajh.23902.
Erba HP. Molecular monitoring to improve outcomes in patients with chronic myeloid leukemia in chronic phase: importance of achieving treatment-free remission. Am J Hematol. 2015 Mar;90(3):242–249.
Published In
Am J Hematol
DOI
EISSN
1096-8652
Publication Date
March 2015
Volume
90
Issue
3
Start / End Page
242 / 249
Location
United States
Related Subject Headings
- Remission Induction
- Randomized Controlled Trials as Topic
- Pyrimidines
- Protein Kinase Inhibitors
- Prognosis
- Piperazines
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Immunology
- Imatinib Mesylate
- Humans